Skip to content
Company Analysis

Gilead Sciences, Inc. GILD

A comprehensive view of key metrics, scores, and financial health for Gilead Sciences, Inc.

Overview of Gilead Sciences, Inc.

GILD NMS
Healthcare Drug Manufacturers - General Large Cap
Gilead Sciences, Inc. (GILD), is a Large Cap company, in the Drug Manufacturers - General industry, last closed at $129.26, about 53.5% overvalued vs fair value, +21.3% 1Y return, placing in the top 25% of its sector.
Metrics Rev Growth 2.4% ROE 40.6% Gross Margin 86.7% Div Yield 2.63%
$129.26
1.18%
As of April 28, 2026
Previous close • Vol 90d: 27.5%
52-Week Range
Market Cap
$160.47B
Enterprise Value
$177.49B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Fair
Completeness: 82%
Confidence: 56%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.gilead.com
HQ Foster City, CA
Employees 17,000
Fiscal year Dec 31

Next Events

Dividend Mar 30
Earnings Apr 23 Estimated

Fair Value Snapshot

Bear Base Bull
$55
$60
$65
Current: $129.26 -54% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$29.4B
2.4%%
Gross Profit
$25.5B
13.4%%
R&D Expense
$5.7B
-3.7%%
Operating Income (EBIT)
$1.7B
-78.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
601.0%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$5.9B
57.5% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
2
Active Leaks
0/2
Improving
1
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Gilead Sciences, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
77
/100
Strong
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
89
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing GILD's balance between Growth (18.6%), Profitability (43.8%), and Safety (37.6%). Growth 19% Safety 38% Profitability 44%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

29th percentile vs peers
29
Key Signals
Rev Growth YoY 2.4% 44p Revenue CAGR 3Y 2.6% 34p TSR 36.4% 63p EPS Growth YoY -91.5% 2p EPS CAGR 3Y -57.4% 3p
Strengths
  • Superior capital returns - 2 return metrics above peer median
  • Operating Margin in top 20% of peers (40.1%, 86th percentile)
  • Gross Profit Margin in top 20% of peers (86.7%, 97th percentile)
  • Net Profit Margin in top 20% of peers (28.9%, 92th percentile)
Risks
  • EPS Growth YoY in bottom 20% of peers (-91.5%)
  • Growth below peer median (percentile: 29)

Profitability

69th percentile vs peers
69
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

59th percentile vs peers
59
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Gilead Sciences, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$60.11
- - -
-53.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info